Biogen Acquires Apellis: Synergies, Risks, And What The Market Is Missing

2026-03-31 14:56:59 ET

Overview

If anyone needed this, it was Apellis' ( APLS ) investors. They are finally getting their exit after the Syfovre safety setback (retinal vasculitis) spoiled its launch party. After a label update and a change to administration instructions, the issue, which was rare to begin with, appeared under control. But APLS never recovered. Syfovre’s image remains damaged to some extent. And with an alternative available in Astellas’ ( ALPMF ) Izervay, Syfovre has underperformed....

Read the full article on Seeking Alpha

For further details see: